ARCHIVES

ODAC Nixes Sanofi’s VTE Drug in 14-1 Vote, Setting High Bar For Adjunctive Therapies

This article is from The Cancer Letter archive.

Vol. 38 No. 25 | June 22, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Clinical Trials Enrollment Drops to 17,500

February 21, 2014

Phase III Study: Lymphoseek Superior to Vital Blue Dye

June 24, 2011

NCI-Approved Clinical Trials

May 26, 2006

“Forward Funding” Will Cost NCI $38 Million, 270 Grants, As OMB Legally Impounds FY 1985 Money

February 1, 1985

Clinical Trials Approved By NCI CTEP During July

August 30, 2002

Also NCI prostate SPOREs plan biospecimen bank.

December 10, 2004